m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05895
 [1]
m6A modification HAGLR HAGLR IGF2BP2 : m6A sites Indirect Inhibition Non-coding RNA miR-106b-5p PTEN  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) READER
 Regulator Info 
m6A Target HOXD antisense growth-associated long non-coding RNA (HAGLR)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-106b-5p microRNA View Details
Regulated Target Mutated in multiple advanced cancers 1 (PTEN) View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators indirectly modulate the functionality of ncRNAs through downstream signaling pathways
Crosstalk Summary HOXD antisense growth-associated long non-coding RNA (HAGLR), epigenetically modified by IGF2BP2 in an m6A-dependent manner, functioned as a sponge for hsa-miR-106b-5p, thereby activating Mutated in multiple advanced cancers 1 (PTEN)/Akt signaling cascade to accelerate DR pathology.
Responsed Disease Diabetic retinopathy ICD-11: 9B71.0
 Disease Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Cell Process Cell proliferation, Cell apoptosis, Cell pyroptosis
Cell viability
In-vitro Model
 HRPE (The human primary retinal pigment epithelium)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
9B71: Retinopathy 12 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name SHP607 Phase 2 [2]
External Link
TTD: D0R1JO
 Compound Name RST-001 Phase 1/2 [3]
Synonyms
ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense
    Click to Show/Hide
External Link
TTD: D0RM6A
 Compound Name ReN-003 Phase 1/2 [4]
Synonyms
Stem cell therapy (retinal diseases), ReNeuron
    Click to Show/Hide
External Link
TTD: D03OVN
 Compound Name PMID28621580-Compound-WO2015089220C70 Patented [5]
External Link
TTD: D07AVU
 Compound Name SIR-1076 Preclinical [6]
Synonyms
Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics
    Click to Show/Hide
External Link
TTD: D06RVY
 Compound Name CytoRet Investigative [4]
Synonyms
Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO
    Click to Show/Hide
External Link
TTD: D0V4YT
 Compound Name LPO-1010CSR Investigative [4]
External Link
TTD: D0MH8K
 Compound Name INDUS-815C Investigative [7]
Synonyms
VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech
    Click to Show/Hide
External Link
TTD: D0IR8J
 Compound Name SF-113 Investigative [4]
External Link
TTD: D0I2AD
 Compound Name SF-106 Investigative [4]
External Link
TTD: D07DRO
 Compound Name Gene therapy, retinopathy, Investigative [4]
Synonyms
Gene therapy (retinopathy)
    Click to Show/Hide
External Link
TTD: D04ENF
 Compound Name Superoxide dismutase mimetics Investigative [4]
Synonyms
INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek
    Click to Show/Hide
External Link
TTD: D03KRF
References
Ref 1 HAGLR, stabilized by m6A modification, triggers PTEN-Akt signaling cascade-mediated RPE cell pyroptosis via sponging miR-106b-5p. J Biochem Mol Toxicol. 2024 Jan;38(1):e23596. doi: 10.1002/jbt.23596. Epub 2023 Dec 13.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT02556736) RST-001 Phase I/II Trial for Retinitis Pigmentosa.
Ref 4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 5 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. doi: 10.1080/13543776.2017.1344215. Epub 2017 Jun 23.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028168)
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2708).